Early Diagnosis & Management of Carcinoid Tumors
|
|
Purpose
|
|
Carcinoid is a very rare and slow-growing tumor that it is often underdiagnosed or misdiagnosed. Even though carcinoid is a slow-growing tumor, it may produce significant and, sometimes, serious symptoms. Carcinoid is potentially life threatening, particularly the atypical type. As the U.S. population continues to grow, the number of carcinoid cases will likely increase as well. Early detection of the tumor can improve the prognosis of this highly treatable condition.
|
|
|
Program Overview
|
|
|
This program has been developed to update and educate gastroenterologists and primary care physicians who provide care for people with carcinoid disease. This program will provide an explanation of why carcinoid is underdiagnosed and give insight into how to distinguish carcinoid from other diseases that may present with similar symptoms. The program also discusses evidence-based methods for treating patients with carcinoid tumors.
|
|
|
Audience
|
|
|
This program has been specifically developed to update and educate gastroenterologists and primary care physicians who provide care for people with gastrointestinal conditions.
|
|
|
Learning Objectives
|
Following completion of this CME activity, participants should be better able to:
- Describe the reasons for the underdiagnosis of carcinoid tumors.
- Distinguish between carcinoid and other conditions that present with similar symptoms based on clinical and laboratory findings.
- Appropriately identify prognostic disease factors when managing patients with carcinoid syndrome.
- Incorporate evidence-based methods for treating patients with carcinoid tumors.
|
|
|
Disclaimer
|
|
The views expressed herein, while consistent with current medical literature, are solely those of the faculty.
|
|
|
Faculty
|
|
|
P. Jay Pasricha, MD (Program Director/Moderator)
Professor of Anatomy and Neurosciences and Biomedical Engineering
University of Texas Medical Branch
>> Read Biography
Lowell Anthony, MD
Associate Professor of Medicine
Louisiana State University
>> Read Biography
David Metz, MD
Professor of Medicine
University of Pennsylvania
>> Read Biography
Irvin Modlin, MD, PhD
Professor of Gastroenterological Surgery
Yale University School of Medicine
>> Read Biography
|
|
|
Faculty Disclosure Information
|
|
|
It is the policy of the AGA to assure balance, independence, objectivity and scientific rigor in all of its directly and jointly sponsored educational activities. All faculty including program committee chairs and planning members participating in any AGA sponsored or jointly-sponsored activity are expected to disclose to the participants any relevant financial relationship or other relationship held within the past 12 months that may pose a potential commercial bias. In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, faculty members for this activity were each asked to complete financial disclosure forms. Disclosures are provided below.
P. Jay Pasricha, MD
Grant/Research Support: Olympus
Consultant: USGI, GI Supply
Lowell Anthony, MD
Grant/Research Support: Novartis Pharmaceuticals Corporation, Mallinckrodt
Speakers' Bureau: Novartis Pharmaceuticals Corporation
David Metz, MD
Grant/Research Support: Novartis Pharmaceuticals Corporation.
Irvin Modlin, MD, PhD
Dr. Modlin has nothing to disclose.
|
|
|
Suggested Minimum Software Requirements
|
|
|
Internet Explorer (4.0 or greater), Windows 98 and Windows Media Player (7.0 or greater), or Adobe Acrobat (5.0 or greater)
|
|
|
Release Date
|
|
|
May 14, 2005
|
|
|
Expiration Date
|
|
|
May 14, 2007
|
|
|
Fee
|
|
|
Free-of-charge
|
|
|
|
Sponsorship and Support
|
|
|
Sponsored by the AGA. Supported through an educational grant from Novartis Pharmaceuticals Corporation.
|
|
|
|
|
|
|
|
